Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMGN $7.63 1.4300 +23.06%
CBMG $16.98 1.1600 +7.33%
CNDO $2.50 0.1500 +6.38%
ARGS $8.32 0.3400 +4.26%
STML $15.48 0.4900 +3.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

EPZM $19.14 -1.4000 -6.82%
GALT $3.22 -0.2300 -6.67%
SRNE $10.09 -0.6900 -6.40%
TGTX $14.24 -0.9100 -6.01%
VSTM $7.30 -0.4100 -5.32%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact

(NASDAQ) Jan 13, 2015 - Intrexon Corporation and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
read article 

NantWorks Announces Launch of an Immuno-Oncology Company, NantCell, and Licensing Agreement with Amgen for an Oncology Antibody

(Yahoo! Finance) Jan 14, 2015 - NantCell, LLC today announced that it has entered into a licensing agreement with Amgen Inc. for AMG 479 (ganitumab), previously in Phase 3 development.
read article 

New Test Helps Guide Treatment for Bone Marrow Transplant Patients with Graft vs. Host Disease

(U-M Health System) Jan 13, 2015 - A new test can guide treatment for patients with graft versus host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants, according to research from the University of Michigan published in Lancet Haematology this month.
read press release 

UCLA Scientists Use ‘NanoVelcro’ and Temperature Control to Extract Tumor Cells from Blood

(UCLA Health) Jan 12, 2015 - An international group led by scientists at UCLA’s California NanoSystems Institute has developed a new method for effectively extracting and analyzing cancer cells circulating in patients’ blood.
read press release 

Children of Melanoma Survivors Need Better Protection from Sun’s Harmful Rays, UCLA Research Shows

(UCLA Health) Jan 13, 2015 - UCLA researchers have found that children of melanoma survivors are not comprehensively adhering to sun protection recommendations, despite them being at an increased risk for developing the disease as adults.
read press release 

Drug for Lou Gehrig’s Disease Boosts Radiation Effectiveness in Melanoma Laboratory Models with Brain Metastasis

(Rutgers/CINJ) Jan 12, 2015 - Research from Rutgers Cancer Institute of New Jersey and the Ernest Mario School of Pharmacy at Rutgers University demonstrates that a drug used to treat Lou Gehrig’s disease (ALS) helps radiation be more effective when it was administered to laboratory models with melanoma that had metastasized to the brain.
read press release 

WVU Research Shows Promise for Reducing Risk of Breast Cancer Spreading to the Brain

(WVU Health News) Jan 12, 2015 - Research seeks to better understand why and how breast cancer can spread to the brain with the goal of developing a way to reduce the risk of this phenomenon.
read article 

Moderately Increased Risk of Colorectal Cancer in T2DM

(Physician's Briefing/HealthDay News) Jan 13, 2015 - Increased risk for diabetes patients with obesity duration of four years or longer.
read article 

Analyzing the Gut Microbiome to Help Detect Colorectal Cancer

(NCI) Jan 13, 2015 - Changes in the gut microbiome could help distinguish individuals with healthy colons from those with either colorectal adenomas (polyps with a risk of becoming cancer) or colorectal cancer, according to results of two recent studies.
read article 

Race, Ethnicity Affect Breast Cancer Survival, Study Shows

( News) Jan 13, 2015 - Your chances of being diagnosed with early breast cancer, as well as surviving it, vary greatly depending on your race and ethnicity, a new study indicates.
read article  

Express Scripts Sees Opportunity to Lower Cancer Treatment Cost

(Reuters) Jan 13, 2015 - Express Scripts, the largest U.S. pharmacy benefit manager, on Tuesday said cost savings on expensive cancer treatments could be achieved if the company were involved earlier in the decision-making process.
read article 

Cancer Drugs Fund Cuts 16 Therapies, Budget Rises

(PharmaTimes [UK]) Jan 12, 2015 - Details of the eagerly-awaited NHS Cancer Drugs Fund review has been released, which shows that its budget will grow but 16 drugs (covering 25 indications) out of 84 drugs will be chopped.
read article 

After Roiling Hepatitis Market, Express Scripts Turns to Cholesterol

(Bloomberg) Jan 13, 2015 - After igniting a price war over hepatitis C medicine that has roiled the pharmaceutical industry, Express Scripts Holding Co. is looking to reap savings from expensive new treatments for cancer and high cholesterol.
read article 

Let Me Die, Chinese Mother Says as Cancer Bills Pile Up

(Bloomberg) Jan 12, 2015 - Across China, families who have ridden the country’s economic boom to prosperity often plummet into financial ruin after a cancer diagnosis. In a nation where most people rely on government health insurance, cancer patients are finding that costs, including expensive drugs, far outstrip coverage.
read article 

Janssen Biotech Strikes $241M Deal for 'Gut Drug' Candidate

(Philadelphia Business Journal/HealthCare Inc. blog) Jan 13, 2015 - Janssen Biotech Inc. entered into a licensing agreement Tuesday for an experimental inflammatory bowel disease treatment under development by Vedanta Biosciences.
read article 

Lilly Says It Couldn't Have Made Tainted Cialis

( Jan 13, 2015 - A batch of Cialis pills, purportedly made at a plant in Australia, was banned from entering the United States after the pills were found to contain the active ingredient for rival erectile-dysfunction drug Viagra.
read article 

U.S. Insurers Squeeze Diabetes Drug Prices : Eli Lilly

(Reuters) Jan 12, 2015 - Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs.
read article 

FDA to Create New Drug Quality Office

(NASDAQ/Dow Jones Business News) Jan 12, 2015 - The Food and Drug Administration plans to create a new Office of Pharmaceutical Quality to focus in part on manufacturing problems such as those that have beset generic companies that make extended-release versions of drugs.
read article 

JPMorgan CEO Dimon Says He Struggled with Disclosing His Cancer

(Reuters) Jan 12, 2015 - Jamie Dimon, the chief executive of JPMorgan Chase & Co, said on Monday that he struggled with having to publicly disclose in July that he had throat cancer.
read article 

Another NICE No for Dendreon Cancer Drug

(Pharmafile [UK]) Jan 13, 2015 - Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for chemotherapy, rejected by NICE for the second time in less than a year.
read article 

Revisions to Molecular Testing Guidelines Continues to Give Hope to Lung Cancer Patients

(MarketWatch) Jan 12, 2015 - The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) are teaming to revise the evidence-based guideline, “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.”
read article 

ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years

(Yahoo! Finance) Jan 13, 2015 - Iclusig commercial opportunity expected to expand -- three new clinical trials to begin in 2015, including a global, randomized trial of Iclusig vs. nilotinib in second-line CML.
read article 

Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome

( Jan 12, 2015 - Amgen and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells.
read article 

Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors

(Bristol-Myers Squibb) Jan 13, 2015 - Bristol-Myers Squibb Company and Eli Lilly and Company announced today a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299).
read corporate press release 

Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

(MarketWatch) Jan 13, 2015 - Combinations of KEYTRUDA® (pembrolizumab) with Alimta® (pemetrexed), Cyramza® (ramucirumab), or necitumumab to be explored.
read article